Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q1

9273.TEDINET S100SAN2
Period2023-07-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥5.8bn2023-07-01 → 2023-09-30Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥5.4bn2022-07-01 → 2022-09-30Cons.Net sales
Operating income¥1.2bn2023-07-01 → 2023-09-30Cons.Operating income
Operating income¥1.0bn2022-07-01 → 2022-09-30Cons.Operating income
Ordinary income¥1.2bn2023-07-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥979m2022-07-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥1.2bn2023-07-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥979m2022-07-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥758m2023-07-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥606m2022-07-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥758m2023-07-01 → 2023-09-30Cons.Profit loss
Net income¥606m2022-07-01 → 2022-09-30Cons.Profit loss
Total assets¥28.7bnat 2023-09-30Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥26.3bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥7.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥21.2bnat 2023-09-30Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥18.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥9.6bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
EPS (basic)¥19.122023-07-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.292022-07-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio74.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥449m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥449m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥15m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2023-09-30¥4.0bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2023-09-30¥3.6bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥449m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2023-09-30¥686m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2023-09-30¥2.2bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2023-09-30¥2.2bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2023-09-30¥526m
—segment totalrevenue2023-07-01 → 2023-09-30¥6.3bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥5.8bn
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥449m
—segment totalsegment profit2023-07-01 → 2023-09-30¥1.2bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30¥6m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥4.0bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥3.5bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥501m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥672m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥337m
—segment totalrevenue2022-07-01 → 2022-09-30¥5.9bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥5.4bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥501m
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 346
ItemContextValueUnit
Profit lossPrior1YTDDuration605900000JPY
Profit lossCurrentYTDDuration757585000JPY
Profit loss attributable to owners of parentPrior1YTDDuration605900000JPY
Profit loss attributable to owners of parentCurrentYTDDuration757585000JPY
Profit lossPrior1YTDDuration605900000JPY
Profit lossCurrentYTDDuration757585000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration260000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration8933000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration-1304000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-2730000JPY
Other comprehensive incomePrior1YTDDuration-1044000JPY
Other comprehensive incomeCurrentYTDDuration6202000JPY
Comprehensive incomePrior1YTDDuration604856000JPY
Comprehensive incomeCurrentYTDDuration763788000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration604856000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration763788000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember3465704000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember1892904000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember5358608000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration5358608000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember501364000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember501364000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-501364000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember3967068000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember1892904000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember5859972000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-501364000JPY
Net salesPrior1YTDDuration5358608000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember672260000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember337249000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember1009509000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember5601000JPY
Operating incomePrior1YTDDuration1015111000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember3593041000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember2230096000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember5823138000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration5823138000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember449077000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember449077000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-449077000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember4042119000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember2230096000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember6272216000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-449077000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2023-09-30pass